<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00598845</url>
  </required_header>
  <id_info>
    <org_study_id>NSD 15501</org_study_id>
    <secondary_id>NSD 15501</secondary_id>
    <secondary_id>REK 96/1478-2</secondary_id>
    <secondary_id>Helse Vest 911351</secondary_id>
    <nct_id>NCT00598845</nct_id>
  </id_info>
  <brief_title>Molecular Markers in Treatment in Endometrial Cancer</brief_title>
  <acronym>MoMaTEC</acronym>
  <official_title>Prospective Study of Endometrial Cancer Treatment in Relation to Molecular Markers in Curettage Specimens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse-Bergen HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bergen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective multicenter trial is to investigate the value of molecular
      markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation
      to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicenter study to investigate the predictive value of molecular
      markers in endometrial cancer for lymph node metastasis, prognosis and treatment. For the
      previously studied tumor markers p53, p16, ER, PR and HER2neu, we want to investigate the
      expression in curettage material in relation to lymph node metastasis and prognosis among
      endometrial carcinoma patients. We also want to investigate the distribution of genetic
      alterations in fresh frozen tumor tissue in order to design prospective randomized treatment
      trials of metastatic endometrial cancer based on molecular profile. There will be a special
      emphasis on disturbances in the pathways influenced by new targeted therapy, such as
      inhibitors of Her2/NEU, EGFR, receptor tyrosine kinase, mTOR, PTEN and hormone receptor
      pathways.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2001</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of lymph node metastases</measure>
    <time_frame>At primary treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent disease, death from disease</measure>
    <time_frame>5 years after primary treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Endometrial Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Consecutive numbers</arm_group_label>
    <description>Patients with endometrial cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tumor biopsy study</intervention_name>
    <description>Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.</description>
    <arm_group_label>Consecutive numbers</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor specimens from endometrial carcinoma, from curettage and hysterectomy specimens,
      formalin-fixed and paraffin-embedded and fresh frozen, stored at minus 80 °C, corresponding
      blood samples with normal DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with endometrial carcinoma that undergo an endometrial biopsy before treatment with
        hysterectomy with bilateral salpingoophorectomy with or without pelvic lymph node staging.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with endometrial carcinoma

          -  Available endometrial biopsy

          -  Informed consent

        Exclusion Criteria:

          -  No informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helga B. Salvesen, Prof., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bergen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Britt Edvardsen, AVD ING</last_name>
    <phone>+4755974200</phone>
    <phone_ext>6336</phone_ext>
    <email>britt.edvardsen@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingjerd Bergo, Tech</last_name>
    <phone>+4755974200</phone>
    <email>ingjerd.bergo@helse-bergen.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gynecological Oncology, UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Amant, MD, PhD</last_name>
      <email>Frederic.amant@uz.kuleuven.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentralsykehuset i Førde</name>
      <address>
        <city>Førde</city>
        <zip>N6807</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tjugum Jostein, MD, PhD</last_name>
      <phone>+4757 83 90 00</phone>
      <email>jostein.tjugum@helse-forde.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helse-Fonna, Haugesund Sjukehus</name>
      <address>
        <city>Haugesund</city>
        <zip>N5528</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Oddenes, MD</last_name>
      <email>Klaus.oddenes@helse-fonna.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kvinneklinikken, Akershus Universitetssykehus</name>
      <address>
        <city>Lørenskog</city>
        <zip>N1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie E Engh, Prof</last_name>
      <email>m.e.engh@medisin.uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kvinnesenteret, Ullevål Universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <zip>N0450</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annetine Staff, MD PhD</last_name>
      <email>annetine.staff@ulleval.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology, St Olav's Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>N7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solveig Tingulstad, Prof</last_name>
      <phone>+4772574957</phone>
      <email>solveig.tingulstad@stolav.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Vestfold HF</name>
      <address>
        <city>Tønsberg</city>
        <zip>N3103</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan A. Rokne, MD</last_name>
      <email>jan.anders.rokne@siv.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gynecology, Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margareth S. Lode, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Senter for Surgical Gynecologic Oncology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janusz Marcickiewicz, MD, PhD</last_name>
      <email>janusz.marcickiewicz@obgyn.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.nsgo.org/</url>
    <description>Nordic Society of Gynecologic Oncology</description>
  </link>
  <reference>
    <citation>Engelsen IB, Stefansson I, Akslen LA, Salvesen HB. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol. 2006 Oct;195(4):979-86. Epub 2006 May 3.</citation>
    <PMID>16677592</PMID>
  </reference>
  <reference>
    <citation>Stefansson IM, Salvesen HB, Akslen LA. Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 2006 Mar 15;66(6):3303-9.</citation>
    <PMID>16540684</PMID>
  </reference>
  <reference>
    <citation>Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006 Jan 10;24(2):268-73. Epub 2005 Dec 5.</citation>
    <PMID>16330673</PMID>
  </reference>
  <reference>
    <citation>Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol. 2004 Apr 1;22(7):1242-52.</citation>
    <PMID>15051772</PMID>
  </reference>
  <reference>
    <citation>Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Haukaas SA, Goffin JR, Bégin LR, Foulkes WD, Akslen LA. Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res. 2002 Dec 1;62(23):6808-11.</citation>
    <PMID>12460889</PMID>
  </reference>
  <reference>
    <citation>Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol. 1999 May;17(5):1382-90.</citation>
    <PMID>10334522</PMID>
  </reference>
  <reference>
    <citation>Wik E, Trovik J, Iversen OE, Engelsen IB, Stefansson IM, Vestrheim LC, Haugland HK, Akslen LA, Salvesen HB. Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting. Am J Obstet Gynecol. 2009 Dec;201(6):603.e1-7. doi: 10.1016/j.ajog.2009.07.029. Epub 2009 Oct 3.</citation>
    <PMID>19800606</PMID>
  </reference>
  <reference>
    <citation>Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4834-9. doi: 10.1073/pnas.0806514106. Epub 2009 Mar 4.</citation>
    <PMID>19261849</PMID>
  </reference>
  <reference>
    <citation>Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8713-7. doi: 10.1073/pnas.0803379105. Epub 2008 Jun 13.</citation>
    <PMID>18552176</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bergen</investigator_affiliation>
    <investigator_full_name>Helga B Salvesen</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Endometrial cancer</keyword>
  <keyword>Molecular markers</keyword>
  <keyword>Lymph node metastasis</keyword>
  <keyword>Prospective study</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Cancer of Endometrium</keyword>
  <keyword>Tumor Markers, Biological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

